BACKGROUND: Primary sclerosing cholangitis (PSC) is characterised by progressive inflammatory and fibrotic destruction of the biliary ducts. There are no effective medical therapies and presently high dose ursodeoxycholic acid is no longer recommended due to significant adverse events in a recent clinical trial. Cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction is associated with PSC in both children and adults. Since CFTR dysfunction leads to altered fatty acid metabolism, specifically reduced docosahexaenoic acid (DHA), we hypothesised that DHA supplementation might be an effective therapy for patients with PSC. AIM: To determine the safety and efficacy of oral DHA supplementation for the treatment of PSC. METHODS: We conducted a 12 month open-label pilot study to evaluate safety of oral DHA and its effects on serum alkaline phosphatase as a primary outcome measure in 23 patients with PSC. DHA was administered orally at 800 mg twice per day. Secondary outcomes included changes in other liver function tests and fibrosis biomarkers. RESULTS: A 1.7-fold increase in serum DHA levels was observed with supplementation. The mean alkaline phosphatase level (±S.E.) at baseline was 357.8 ± 37.1 IU compared to 297.1 ± 23.7 IU (P < 0.05) after 12 months of treatment. There were no changes in other liver function tests and fibrosis biomarkers. No adverse events were reported. CONCLUSIONS: Oral DHA supplementation is associated with an increase in serum DHA levels and a significant decline in alkaline phosphatase levels in patients with PSC. These data support the need for a rigorous trial of DHA therapy in PSC.
BACKGROUND:Primary sclerosing cholangitis (PSC) is characterised by progressive inflammatory and fibrotic destruction of the biliary ducts. There are no effective medical therapies and presently high dose ursodeoxycholic acid is no longer recommended due to significant adverse events in a recent clinical trial. Cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction is associated with PSC in both children and adults. Since CFTR dysfunction leads to altered fatty acid metabolism, specifically reduced docosahexaenoic acid (DHA), we hypothesised that DHA supplementation might be an effective therapy for patients with PSC. AIM: To determine the safety and efficacy of oral DHA supplementation for the treatment of PSC. METHODS: We conducted a 12 month open-label pilot study to evaluate safety of oral DHA and its effects on serum alkaline phosphatase as a primary outcome measure in 23 patients with PSC. DHA was administered orally at 800 mg twice per day. Secondary outcomes included changes in other liver function tests and fibrosis biomarkers. RESULTS: A 1.7-fold increase in serum DHA levels was observed with supplementation. The mean alkaline phosphatase level (±S.E.) at baseline was 357.8 ± 37.1 IU compared to 297.1 ± 23.7 IU (P < 0.05) after 12 months of treatment. There were no changes in other liver function tests and fibrosis biomarkers. No adverse events were reported. CONCLUSIONS: Oral DHA supplementation is associated with an increase in serum DHA levels and a significant decline in alkaline phosphatase levels in patients with PSC. These data support the need for a rigorous trial of DHA therapy in PSC.
Authors: S D Freedman; M H Katz; E M Parker; M Laposata; M Y Urman; J G Alvarez Journal: Proc Natl Acad Sci U S A Date: 1999-11-23 Impact factor: 11.205
Authors: Peter P Stanich; Einar Björnsson; Andrea A Gossard; Felicity Enders; Roberta Jorgensen; Keith D Lindor Journal: Dig Liver Dis Date: 2011-01-19 Impact factor: 4.088
Authors: Steven D Freedman; Deborah Weinstein; Paola G Blanco; Pedro Martinez-Clark; Serge Urman; Munir Zaman; Jason D Morrow; Juan G Alvarez Journal: J Appl Physiol (1985) Date: 2002-05
Authors: Sunil Sheth; Julie C Shea; Michele D Bishop; Sanjiv Chopra; Meredith M Regan; Emily Malmberg; Carolyn Walker; Ryan Ricci; Lap-Chee Tsui; Peter R Durie; Julian Zielenski; Steven D Freedman Journal: Hum Genet Date: 2003-06-03 Impact factor: 4.132
Authors: Keith D Lindor; Kris V Kowdley; Velimir A C Luketic; M Edwyn Harrison; Timothy McCashland; Alex S Befeler; Denise Harnois; Roberta Jorgensen; Jan Petz; Jill Keach; Jody Mooney; Carol Sargeant; Julie Braaten; Tamara Bernard; Debra King; Ellen Miceli; Jeff Schmoll; Tanya Hoskin; Prabin Thapa; Felicity Enders Journal: Hepatology Date: 2009-09 Impact factor: 17.425
Authors: J E Eaton; B D Juran; E J Atkinson; E M Schlicht; X Xie; M de Andrade; C S Lammert; V A Luketic; J A Odin; A A Koteish; K V Kowdley; K B Chopra; G M Hirschfield; N P Chalasani; K N Lazaridis Journal: Aliment Pharmacol Ther Date: 2015-03-17 Impact factor: 8.171
Authors: Nandini Krishnamoorthy; Raja-Elie E Abdulnour; Katherine H Walker; Braden D Engstrom; Bruce D Levy Journal: Physiol Rev Date: 2018-07-01 Impact factor: 37.312
Authors: Ali Taylan; Oguz Gurler; Burak Toprak; Ali Riza Sisman; Hulya Yalcin; Ayfer Colak; Ismail Sari Journal: J Korean Med Sci Date: 2015-08-13 Impact factor: 2.153